Sundar Jagannath, MD:

Chief, Multiple Myeloma and Bone Marrow Transplantation Program, Saint Vincent’s Comprehensive Cancer Center New York, New York; Professor of Medicine, New York Medical College, Valhalla, New York

Sundar Jagannath, MD, a board-certified specialist in internal medicine and medical oncology, is the chief of Bone Marrow and Blood Stem Cell Transplantation at St. Vincent’s Comprehensive Cancer Center in New York, New York, where he also serves as the chief of Multiple Myeloma Service. In addition, Dr. Jagannath has held the position of professor of medicine at New York Medical College since 1999.

Dr. Jagannath received his medical degree in 1974 at Maharaja Sayajirao University in Baroda, India and continued his medical training with a fellowship in immuno-virology at McMaster University Medical Center in Hamilton, Ontario, Canada. His residency was completed at the Bronx-Lebanon Hospital and at Harper-Grace Hospital, Wayne State University in Detroit. Dr. Jagannath also completed a medical oncology fellowship at UTSCC-MD Anderson Hospital and Tumor Institute in Houston.

He is a former professor of pathology and medicine at the University of Arkansas. He also was the Chief of Bone Marrow Transplantation at the University of Arkansas from 1989 to 1997.

Dr. Jagannath is widely respected for his knowledge and accomplishments in bone marrow transplantation. He has published extensively on topics concerning multiple myeloma and bone marrow transplantation and is often an invited lecturer at professional organizations' annual meetings. He is a reviewer for several journals, including American Journal of Hematology, Blood, Bone Marrow Transplantation, and Journal of Clinical Oncology. He is an active member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Bone and Marrow Transplantation. In 2003, Dr Jagannath was a recipient of the Humanitarian Award from the Multiple Myeloma Research Foundation.

Robert Z. Orlowski, MD, PhD

Lenvel Lee Rothrock Associate Professor of Medicine, Division of Hematology/Oncology and Pharmacology, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Robert Z. Orlowski, MD, PhD, a board-certified specialist in internal medicine and medical oncology, serves as both Lenvel Lee Rothrock associate professor of medicine at the Lineberger Comprehensive Cancer Center and associate professor in the Department of Pharmacology at the University of North Carolina at Chapel Hill. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University in 1990 and his medical degree from the Yale University School of Medicine in 1991. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis Medical Center. Dr. Orlowski continued his medical education with fellowships in both medical oncology and hematology at the Johns Hopkins Hospital and School of Medicine before becoming a senior clinical fellow at Johns Hopkins Oncology Center.

Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy, with a focus on the molecular pathogenesis of oncologic disease processes and the mechanisms of action of chemotherapeutics. A particular area of interest for his laboratory research efforts has been the role of the ubiquitin-proteasome pathway in tumorigenesis and as a target for cancer therapy. On the clinical research front, his efforts have focused on translation of promising laboratory-based findings into novel clinical trials focusing on patients with hematologic malignancies. He has published in, and is a reviewer for, several journals, including Blood, Cancer Research, Journal of Clinical Oncology, and the New England Journal of Medicine. Dr. Orlowski is an active member of the North Carolina Oncology Association, the American Society of Hematology, the American Association of Cancer Research, and the American Society of Clinical Oncology. He is the recipient of several awards, including the Leukemia and Lymphoma Society Scholar in Clinical Research and the Jefferson-Pilot Fellowship in Academic Medicine.

Paul G. Richardson, MD

Associate Professor of Medicine, Harvard Medical School; Clinical Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Boston, Massachusetts

Paul G. Richardson, MD, earned his medical degree from the Medical College of St. Bartholomew's Hospital, University of London and was chief resident at the Royal Marsden Hospital, London before coming to the United States. Dr. Richardson completed a clinical fellowship in hematology and medical oncology at Baystate Medical Center, Tufts University School of Medicine. He was a visiting fellow at Dana Farber in 1993 and joined as junior faculty in 1994, spending 5 years with Cancer Pharmacology and the Solid Tumor Autologous Marrow Program. During this time, he completed a medical residency at Beth Israel Hospital and then joined the Jerome Lipper Multiple Myeloma Center in 1999, becoming its clinical director in 2001.

Dr. Richardson is board certified in internal medicine, hematology, and medical oncology. He is a member of several professional organizations, including the British Medical Association, the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physicians. Dr. Richardson has received several awards, including the George P. Canellos Award for Excellence in Clinical Research in 2004.

Dr. Richardson has been an author or co-author in over 100 original articles in peer-reviewed publications, including the Journal of Clinical Oncology,Clinical Cancer Research, and the New England Journal of Medicine, as well as over 80 reviews, editorials, and book chapters. Dr. Richardson’s primary research interest is in novel therapies for myeloma, and he has been a leader in the clinical development of bortezomib and lenalidomide for the treatment of myeloma.